Concussion Global Market Report 2024

The concussion market size has grown steadily in recent years. It will grow from $7.63 billion in 2023 to $7.91 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The observed growth in the historical period can be attributed to several factors. These include heightened awareness and educational efforts regarding concussions and their effects, the rise in sports participation leading to an increase in related injuries, the implementation of more stringent regulations within sports governing bodies regarding head injuries, advancements in diagnostic tools enabling more accurate detection and diagnosis of concussions, and the recognition of legal and ethical implications surrounding the management of concussions in various contexts.

The concussion market size is expected to see steady growth in the next few years. It will grow to $9.27 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. Anticipated growth in the forecast period can be attributed to several key factors. These encompass a sustained emphasis on sports safety, ongoing research and advancements in treatment methodologies related to concussions, a rising adoption of comprehensive concussion protocols across sports and healthcare domains, an increasing public health concern regarding head injuries, and collaborative efforts between the medical and sports communities for improved concussion management. Key trends expected in this period include the emergence of teleconcussion services and remote monitoring technologies, educational initiatives aimed at preventing concussions, dedicated research focusing on long-term effects and conditions such as chronic traumatic encephalopathy (CTE), the widespread implementation of concussion protocols within sports organizations, the development of neuroprotective therapies to minimize the impact of concussions, and the formulation of legislation and regulations addressing concussion management across various sectors.

The growth of the concussion market is anticipated to be propelled by an increase in the prevalence of brain injuries. Brain injuries encompass a range of damages affecting the brain, resulting in diverse physical, cognitive, and emotional impairments. Timely and appropriate treatment of concussions is crucial for mitigating the impact of brain-related injuries on overall brain health. This involves practices such as physical and cognitive rest, symptom management, and a gradual return to activities. The escalation in traffic accidents has also contributed to the higher incidence of brain injuries. According to a January 2023 article from the National Center for Biotechnology Information (NCBI), an estimated 1.7 million people in the United States experience traumatic brain injuries annually, with individuals aged 15 to 19 and seniors aged 65 and older facing the highest risk. Moreover, primary malignant tumors of the brain and spinal cord are expected to impact thousands of people in the US. Consequently, the increasing prevalence of brain injuries is a key driver of the concussion market.

The growth trajectory of the concussion market is further expected to be influenced by the rise in the prevalence of neurological diseases. Neurological diseases constitute a diverse range of medical conditions affecting the nervous system, encompassing the brain, spinal cord, and peripheral nerves. Traumatic brain injuries, often involving concussions, are significant contributors to the initiation, exacerbation, or complications of various neurological diseases such as chronic traumatic encephalopathy (CTE) or post-concussion syndrome. As of February 2023, the World Health Organization (WHO) reports that epilepsy, a neurological disease, affects approximately 5 million people globally. High-income countries witness 49 cases per 100,000 individuals, while low- and middle-income countries experience up to 139 cases per 100,000. The prevalence of neurological diseases, therefore, plays a pivotal role in driving the growth of the concussion market.

Product innovation stands out as a prominent trend shaping the landscape of the concussion market. Leading companies in this market are directing their efforts towards developing innovative products to enhance their diagnostic capabilities and maintain a competitive edge. One notable example is TecTraum Inc., a US-based medical device designer, and Nottingham-Spirk Design Associates Inc., a US-based product design firm, who collaborated to introduce pro2cool in May 2022. Recognized as the world's first point-of-care treatment for concussions, pro2cool is a groundbreaking noninvasive hypothermic treatment device. Engineered to alleviate the severity of concussion symptoms, it aims to expedite patients' recovery to their pre-injury baseline. The device achieves this by locally cooling the head and neck, thereby lowering blood temperature before it reaches the brain. Clinical investigations have shown promising results, indicating significant improvements in clinical outcomes when the brain is cooled within days following a concussion.

Major players are embracing strategic partnerships as a proactive approach to raise awareness about the gravity of concussions. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. An illustrative instance of such collaboration is the partnership between Abbott Laboratories, a US-based medical device company, and the Brain Injury Association of America (BIAA), a US-based national organization. Formed in December 2022, this alliance aims to heighten awareness about the seriousness of concussions and emphasize the importance of seeking care for potential concussions. The coalition, comprising nearly twenty advocacy groups, addresses the alarming fact that more than half of individuals suspecting a concussion fail to seek medical evaluation. This strategic collaboration is positioned to play a crucial role in raising public consciousness about concussion-related issues.

In August 2023, Oxeia Biopharmaceuticals Inc., a clinical-stage biotech company based in the United States, successfully acquired SUN11031, a synthetic human ghrelin compound, from Kinemed Inc., another U.S.-based pharmaceutical research and development firm. The financial details of this transaction were not disclosed. This strategic acquisition by Oxeia Biopharmaceuticals aims to leverage SUN11031, which will be developed under the designation OXE103, as a potential treatment for concussions and acute neurotrauma.

Major companies operating in the concussion market report are Pfizer Inc., Novartis AG, Sanofi SA, Abbott Laboratories, Medtronic PLC, Viatris Inc., Zydus Lifesciences Ltd., Integra LifeSciences Corporation, Nihon Kohden Corporation, Raumedic AG, Lupin Limited, NeuroPace Inc., Compumedics Limited, NeuroLogica Corporation, Neural Analytics Inc., NovaSignal Corp., Back Bay Life Science Advisors, BrainScope Company Inc., Neuro Kinetics Inc., ImPACT Applications Inc., NanoDx Inc., Neuren Pharmaceuticals Limited, Advanced Brain Monitoring Inc., ElMindA Ltd., NeurOptics Inc., InfraScan Inc., Neuro Assessment Systems Inc., NeuroTrauma Sciences LLC, SyncThink Inc., Oxeia Biopharmaceuticals Inc., Oculogica Inc., Banyan Biomarkers Inc., Emotiv Inc., BioDirection Inc., Neurologic Wellness Institute.

North America was the largest region in the concussion market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the concussion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the concussion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Concussion assessments primarily revolve around diagnosis and treatment. Diagnosis involves identifying the medical condition or injury through a comprehensive assessment of symptoms, medical history, and various diagnostic tests. These tests often include imaging tools such as magnetic resonance imaging (MRI), X-rays, computed tomography (CT), as well as monitoring devices and other diagnostic equipment. These assessments are utilized by a range of healthcare facilities such as hospitals, clinics, diagnostic centers, and medical camps to evaluate and manage concussions.

The concussion market research report is one of a series of new reports that provides concussion market statistics, including the concussion industry's global market size, regional shares, competitors with a concussion market share, detailed concussion market segments, market trends and opportunities, and any further data you may need to thrive in the concussion industry. This concussion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The concussion market consists of revenues earned by entities by providing concussion services such as consultations, diagnostic tests, imaging studies, CT scans, MRIs, and specialized diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The concussion market also includes sales of medications such as pain relievers, anti-nausea medication, or drugs targeting sleep disturbances or mood disorders. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.